The FDA has accepted Sun Pharmaceutical Industries’ new drug application for OTX-101, an aqueous solution intended for treatment of dry eye disease, the company announced in a press release.
OTX-101 is a preservative-free nanomicellar formulation of cyclosporine A 0.09%, which is now under review following positive topline results of a confirmatory phase 3 study. In the 12-week trial, 744 patients with dry eye were treated with OTX-101 or vehicle, and OTX-101 demonstrated “both efficacy and faster onset of action in a trial environment,” Abhay Gandhi, CEO, North America
Uncategorized